ACORN-HAI alert: Asia’s hospitals facing an accelerating “superbug” emergency

A recent multicountry surveillance initiative led by the Asian Collaboration for Research on Nosocomial Infections (ACORN-HAI) paints a stark picture: health-care-associated infections (HAIs) in hospitals across Asia are widespread, and antimicrobial resistance (AMR) is rapidly eroding the effectiveness of standard treatments. Using prospectively harmonised methods across a range of facilities – from large urban referral centres to district hospitals – the project provides one of the most systematic snapshots to date of how drug‑resistant organisms are undermining patient safety inside hospitals.

Major findings: what the surveillance showed

ACORN-HAI documented a high prevalence of infections that are difficult or impossible to treat with commonly used antibiotics. Key observations included:

• Frequent involvement of multidrug‑resistant Gram‑negative bacteria in pneumonia, bloodstream infections and surgical‑site infections.
• Regular detection of Klebsiella pneumoniae, Acinetobacter spp. and Pseudomonas aeruginosa carrying resistance to critical antibiotics such as carbapenems, colistin and fluoroquinolones.
• Delayed initiation of pathogen‑targeted therapy because many hospitals lack rapid diagnostic capacity, contributing to worse clinical outcomes.
• Excess deaths and longer hospital stays attributable to hospital‑onset sepsis and ventilator‑associated pneumonia (VAP).

These regional findings fit within a troubling global context: a comprehensive 2019-based analysis (published in 2022) estimated roughly 1.27 million deaths were directly attributable to AMR in that year, with nearly 5 million deaths associated with resistant infections. Those global figures underscore the role of hospital transmission in a much larger public‑health crisis.

Why it matters now: strained systems and shifting demographics

Health systems across Asia continue to absorb the aftermath of the COVID-19 pandemic while coping with expanding burdens of chronic disease and ageing populations. In this environment, hospitals can unintentionally amplify resistant pathogens unless infection prevention, diagnostics and antimicrobial stewardship are prioritised. Everyday interventions – inserting central venous lines, operating on older patients, or providing mechanical ventilation – carry increasing risk when secondary infections are driven by organisms that resist first-line and last‑line therapies.

Intensive care: the epicentre of hospital transmission

Critical care units emerged from ACORN-HAI as particularly vulnerable. Active, daily case review and focused surveillance demonstrated rising rates of ICU‑acquired sepsis and VAP, often developing later in prolonged admissions. These infections were disproportionately caused by multidrug‑resistant Gram‑negative organisms and were associated with greater in‑hospital mortality and longer durations of mechanical ventilation.

Contributing system weaknesses included overcrowded units with limited isolation rooms, protracted turnaround times for cultures and susceptibility testing, and variable access to last‑resort antimicrobials. Where diagnostic and infection‑control tools were under-resourced, the human cost was highest.

Critical‑care patterns and implications

• ICU prevention bundles are often implemented but not consistently sustained, and infections continue to rise in many units.
• Multidrug‑resistant pathogens dominate the microbiology of ICU‑onset VAP and sepsis.
• Common ICU performance measures can miss infection‑related deterioration, masking the full toll of HAIs.
• Hospitals with constrained lab services and limited drug formularies experience the worst excess mortality linked to HAIs.

Key pathogens and their clinical consequences

The surveillance repeatedly identified a small group of organisms driving the most severe outcomes:

• Klebsiella pneumoniae – rising carbapenem resistance has been tied to higher ICU death rates and reduced treatment options.
• Acinetobacter spp. – frequently multidrug‑resistant, capable of persisting in the hospital environment and provoking protracted outbreaks.
• Pseudomonas aeruginosa – resistance to fluoroquinolones and other agents limits safe therapeutic choices for ventilator‑associated and device‑related infections.

Think of a hospital ward like a busy train station: one infected traveller boarding a carriage can seed infections throughout the network unless ticket checks (screening), station staff (IPC teams) and surveillance systems (labs and dashboards) are all actively working to spot and isolate the risk.

Primary drivers behind the outbreaks

Several interrelated factors accelerate the propagation of AMR within hospitals:

• Poor or delayed microbiology results that force clinicians to rely on empiric broad‑spectrum antibiotics.
• Gaps in sustained infection prevention and control (IPC) practices, including suboptimal device care and environmental cleaning.
• Inconsistent antimicrobial stewardship activities and limited specialist input for complex cases.
• Insufficient workforce capacity and training for frontline staff to implement IPC and stewardship measures consistently.

Practical interventions: what works and why

ACORN-HAI investigators and independent experts recommend a bundled approach that combines faster detection, robust prevention, and smarter antibiotic use. Priority measures include:

• Expand diagnostic services: around‑the‑clock microbiology, automated blood culture systems, and point‑of‑care molecular tests to reduce time to targeted therapy and limit unnecessary broad‑spectrum antibiotic exposure.
• Reinforce IPC consistently: maintain device‑care bundles for central lines and ventilators, ensure routine environmental disinfection, and create reliable cohorting or isolation capacity.
• Institutionalise antimicrobial stewardship: establish dedicated teams, integrate stewardship rounds into ICU practice, and use regular audit‑and‑feedback to guide prescribing.
• Implement real‑time surveillance: connect laboratory results with ward dashboards and regional networks so emerging resistance triggers rapid containment actions.
• Invest in people: protected time for nurses, pharmacists and junior clinicians to receive training and to apply IPC and stewardship consistently at the bedside.

Practical examples from other settings illustrate potential gains: hospitals that paired rapid diagnostics with stewardship interventions saw quicker narrowing of empiric therapy and reductions in ICU length of stay; sustained hand‑hygiene and device‑care audits produced measurable declines in HAI rates within months. These are not theoretical wins – they are reproducible, evidence‑based improvements when systems are committed and resourced.

Policy actions: financing, governance and regional coordination

Short‑term project funding is unlikely to deliver durable change. Policymakers should prioritise sustained, ring‑fenced investment in laboratory networks, IPC staffing and stewardship infrastructure. Key policy steps include:

• Embedding resistance surveillance into national health information systems to enable anticipatory, rather than reactive, policy responses.
• Creating transparent reporting pathways to regional platforms so cross‑border threats are identified rapidly and mutual assistance can be mobilised.
• Aligning procurement and reimbursement policies to ensure reliable access to essential diagnostics and last‑line antimicrobials where clinically indicated.
• Supporting workforce development and retention strategies so hospitals have the trained personnel needed to sustain IPC and stewardship programmes.

When governments compare the upfront cost of these investments with the downstream human and economic toll – longer hospital stays, repeated ICU admissions, and preventable deaths – the case for sustained funding becomes compelling. Past modelling exercises have warned of severe global social and economic impacts if AMR is left unchecked; translating those warnings into concrete national plans is now urgent.

Conclusion: from measurement to sustained action

ACORN-HAI has established a stronger evidence base for where HAIs occur, which pathogens cause the worst outcomes, and where system gaps lie. The surveillance offers a practical roadmap: amplify rapid diagnostics, shore up IPC, formalise stewardship, and fund these efforts on an ongoing basis. If hospital leaders, civil servants and funders translate these insights into durable programmes, hospitals across Asia can shift from being sources of transmission to resilient barriers against superbugs.

Absent decisive and sustained action, the signals identified by surveillance will continue to manifest as rising morbidity and mortality at the bedside. With investment and coordinated implementation, the region has a real chance to reduce the burden of drug‑resistant disease and protect patients now and into the future.